Vardenafil Increases Penile Rigidity  and Tumescence in Men with Erectile  Dysfunction after a Single Oral Dose

Stark, Stefanie; Sachse, Richard; Liedl, T.; Hensen, J.; Rohde, G.; Wensing, Georg; Horstmann, Rolf D.; Schrott, K. M.

doi:10.1159/000049770

Cited by 99 publications

(74 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second-generation PDE5 inhibitors, which may provide greater specificity and potency, and/or longer duration of action, have shown promising results in clinical trials. 7,8 Information available from clinical trials using sublingual apomorphine, a centrally acting dopaminergic receptor agonist, suggests that it may be an alternative for patients with ED. 12,13 However, apomorphine has a narrow therapeutic window and syncopal events have been reported, particularly when ethanol is coadministered.…”

Section: Discussionmentioning

confidence: 99%

“…Owing to the potentiation of hypotension by the combination of sildenafil and organic nitrates, sildenafil is contraindicated in patients taking organic nitrates. Second-generation PDE5 inhibitors approved or currently under consideration for approval in the US include Levitra s (Vardenafil) 7 and Cialis s (Tadalafil, IC351) 8 , respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

Diamond

Earle

Rosen³

et al. 2004

Int J Impot Res

115

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

Diamond

Earle

Rosen³

et al. 2004

Int J Impot Res

115

View full text Add to dashboard Cite

“…Conversely, cGMP-speci®c phosphodiesterase (PDE) inhibitors, which prevent the hydrolysis of cGMP, allow for the accumulation of cGMP in the cells and potentiate the NOcGMP axis (Jeremy et al, 1997;Gonzalez-Cadavid et al, 1999). Furthermore, type 5 PDE inhibitors, such as sildena®l, vardena®l and tadala®l (IC351) prolong penile tumescence in the presence of sexual stimulation and are amongst the most eective treatments for erectile dysfunction (Boolell et al, 1996;Jeremy et al, 1997;Goldstein et al, 1998;Andersson, 2001;Kim et al, 2001;Padma-Nathan et al, 2001;Stark et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase

Cashen

MacIntyre

Martin

2002

British J Pharmacology

View full text Add to dashboard Cite

1 Using an in vivo model of erectile activity, the eects of sildena®l were studied in mice lacking neuronal or endothelial nitric oxide synthase (nNOS and eNOS, respectively). 2 Under pentobarbitone anaesthesia, intracavernous pressure (ICP) and mean arterial pressure (MAP) were monitored continuously in wild-type, nNOS7/7 and eNOS7/7 mice. The magnitude of erectile activity was quanti®ed as the ratio of ICP to MAP. 3 No dierences in basal ICP or MAP were observed amongst wild-type, eNOS7/7 and nNOS7/7 mice. Electrical stimulation of the cavernous nerve (ESCN; 4.0 V, 16 Hz, 1 ms, 30 s) evoked increases in ICP and ICP/MAP as well as penile tumescence. Responses to ESCN were reduced in nNOS7/7, but not in eNOS7/7 mice. 4 L-NAME (50 mg kg 71 , i.v.) signi®cantly increased MAP and attenuated erectile responses in both wild-type and eNOS7/7 mice. 5 Sildena®l (1 mg kg 71 , i.v.) augmented electrically-evoked erectile activity in a voltage-dependent manner in wild-type mice and facilitated erectile responses in eNOS7/7 mice. By contrast, sildena®l failed to augment the diminished erectile responses in mice lacking the nNOS isoform. 6 These data reveal the relative importance of nNOS, compared to eNOS, as the critical NOS isoform in the control of erectile function and illustrate that the nNOS isoform is required for sildena®l-induced facilitation of erectile responses in vivo in mice.

show abstract

“…These studies were performed to assess the effect of the drug during RigiScan studies in 42 men who had had mild-tomoderate erectile dysfunction for more than 6 months. 4,5 The studies were performed in two centers with different dosing schedules. These results showed that the time to maximum plasma concentration of vardenafil was 0.7 -0.9 h. This number decreased to half in 4 -5 h and was unrecordable after all doses by 24 h.…”

Section: Initial Pharmacokinetic and Efficacy Studiesmentioning

confidence: 99%

Vardenafil: update on clinical experience

Pryor

2002

Int J Impot Res

View full text Add to dashboard Cite

Vardenafil, a potent and selective phosphodiesterase 5 inhibitor, has entered phase 3 clinical trials. Pharmacodynamic studies showed that the maximum plasma concentration after oral administration of 20 -40 mg of vardenafil occurred in 0.7 -0.9 h, the half-life was 4 -5 h, and negligible amounts remained in the circulation after 24 h. The efficacy of vardenafil compared with placebo was shown in RigiScan studies, a phase 2 study involving 601 men with mild-tosevere erectile dysfunction for at least 6 months, and a phase 3 study involving 452 diabetic men. Adverse effects were not severe and tended to decrease with time.

show abstract

Vardenafil Increases Penile Rigidity and Tumescence in Men with Erectile Dysfunction after a Single Oral Dose

Cited by 99 publications

References 17 publications

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase

Vardenafil: update on clinical experience

Contact Info

Product

Resources

About